The core team has experience in the full life cycle of pharmaceutical research and development. The core pipeline is in the leading position among its peers, and other pipelines have unlimited potential. CS0159 targeting FXR has completed US clinical Phase 1, and Phase 2 will be initiated immediately; The orphan drug designation (ODD) for primary sclerosing cholangitis (PSC) has been granted in September of 2021. CS060304 has entered IND enabling in December of 2022. Multiple lead compounds have shown great efficacy in animal models and preclinical candidate compounds (PCCs) will soon to be determined in the near future.